Singapore's Duke-NUS Medical School has achieved a groundbreaking advancement in regenerative medicine, demonstrating that blocking the protein interleukin-11 (IL-11) can enable damaged organs to self-repair. This discovery, originating from preclinical studies, has rapidly progressed to Phase 2 clinical trials, positioning Duke-NUS at the forefront of global biomedical innovation.
The research reveals IL-11, once considered protective, as a key driver of fibrosis—the scarring process that impairs organ function in conditions like kidney failure, liver disease, heart failure, and idiopathic pulmonary fibrosis (IPF). By inhibiting IL-11 signaling, scientists observed not just halted progression but actual reversal of damage, with organs exhibiting regenerative capacity in mouse models. This has profound implications for treating chronic diseases affecting millions worldwide, particularly in an ageing population like Singapore's.
🧬 The Science Behind IL-11 and Fibrosis
Fibrosis occurs when excessive scar tissue replaces healthy organ cells, leading to progressive failure. Traditional targets like transforming growth factor-beta 1 (TGF-β1) have failed clinically due to toxicity. Duke-NUS researchers upended this paradigm in 2017 by identifying IL-11 as the dominant profibrotic cytokine, surpassing TGF-β1 in potency across heart, kidney, liver, and lung tissues.
IL-11 triggers a cascade of inflammation, extracellular matrix deposition, and cell death, stifling repair mechanisms. In human and animal models, elevated IL-11 correlates with disease severity. Blocking it with neutralizing antibodies deactivates this pathway, reducing inflammation and reactivating endogenous regeneration programs.
Kidney Regeneration: A World First
In a landmark 2023 study, Duke-NUS and National Heart Centre Singapore (NHCS) teams showed blocking IL-11 reversed chronic kidney disease (CKD) in mice. Damaged kidneys regained over 50% function, with tubule cells proliferating to 'grow back' tissue—a feat unprecedented for diseased organs. This step-by-step process involved:
- Neutralizing IL-11 to halt scarring.
- Reactivating progenitor cells for tubule repair.
- Restoring filtration and metabolic functions.
Long-term safety was confirmed, with no adverse effects over months.
Liver and Heart Repair Mechanisms
Similar results emerged for liver regeneration post-injury and heart fibrosis reversal. In acetaminophen-induced liver damage models, anti-IL-11 therapy promoted hepatocyte proliferation while curbing stellate cell activation. Heart studies showed reduced cardiomyocyte death and improved ejection fraction, highlighting IL-11's pan-organ role.
From Bench to Bedside: Licensing and Phase 2 Trials
Duke-NUS's translational prowess shone through rapid commercialization. In 2019, spin-off Enleofen Bio licensed anti-IL-11 antibodies to Boehringer Ingelheim for up to $1B per product. BI 765423 completed Phase 1, demonstrating safety, and entered Phase 2a for IPF in January 2026 (NCT07036523)—the first fibrotic drug originating from Singapore academia.
Trials assess lung function improvement alongside standard care. Other firms like Mabwell advance similar antibodies for scarring, underscoring IL-11's broad potential. For details on the foundational aging study, refer to the Nature publication.
Duke-NUS: Singapore's Research Powerhouse
Established in 2005 as a Duke University-NUS partnership within SingHealth Duke-NUS Academic Medical Centre, Duke-NUS emphasizes PhD-integrated MD training and translational research. Located in Biopolis—Singapore's biomedical hub—it fosters interdisciplinary work with A*STAR and industry.
The Cardiovascular & Metabolic Disorders (CVMD) Programme, home to IL-11 work, exemplifies this. With over 700 faculty driving 1,000+ publications yearly, Duke-NUS ranks among Asia's top med schools, boosting Singapore's status as a global R&D node.
Spotlight on Lead Researchers
Asst Prof Anissa Widjaja, molecular biologist, spearheaded IL-11 discovery, authoring high-impact papers. Prof Stuart Cook, CVMD director, provides clinical oversight. Their synergy exemplifies Duke-NUS's clinician-scientist model.
Boosting Singapore's Biomedical Ecosystem
This breakthrough elevates Singapore's Biopolis, attracting $25B+ investments. It highlights government support via NMRC grants, enhancing higher ed's role in economic growth. Duke-NUS trains next-gen researchers via PhD programmes in Integrated Biology & Medicine (IBM) and Clinical & Translational Sciences (CTS), focusing on fibrosis pathways.
Collaborations with NHCS integrate research into care, yielding real-world impact.
Career Opportunities in Singapore's Med Research
Duke-NUS's success spurs demand for PhDs, postdocs in fibrosis, regen med. Singapore offers competitive salaries (S$80K+ entry PhD), scholarships like A*STAR. Roles in trials, spin-offs abound, drawing global talent.
- PhD scholarships with stipends.
- Postdoc fellowships in CVMD.
- Industry partnerships for tech transfer.
Challenges and Future Outlook
While promising, human translation needs rigorous trials. Phase 2 data expected 2027+. Broader applications for ageing, CKD (affecting 1-in-10 Singaporeans) loom. Duke-NUS eyes multi-organ trials, solidifying Singapore's leadership.
Explore opportunities at Duke-NUS PhD programmes.
Photo by Galt Museum & Archives on Unsplash
Stakeholder Perspectives
Patients hail potential dialysis escape; experts praise translational speed. Policymakers view it as biomed jewel. Students inspired for research careers.
